Asuragen In-licenses BRAF Mutation from Johns Hopkins | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen said today that it has obtained a non-exclusive license from Johns Hopkins University to incorporate a BRAF mutation sequence into its molecular diagnostic products.

Terms of the licensing deal includes the use of the mutation, BRAF V600E, as a component in diagnostic test kits and use of it in Asuragen's CLIA laboratory for clinical research and patient testing. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.